Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Citius licences Novellus’ stem cell therapy for Covid-19-related ARDS

pharmaceutical-technologyApril 03, 2020

Tag: Citius Pharmaceuticals , COVID-19 , Novellus , ARDS

PharmaSources Customer Service